Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA.
Curr Urol Rep. 2011 Dec;12(6):396-403. doi: 10.1007/s11934-011-0219-8.
Patients with Parkinson's disease (PD) commonly develop lower urinary tract symptoms (LUTS) as their disease severity progresses. It is a well-established fact that neurodegeneration of the nigrostriatal dopaminergic pathway occurs in PD. This neurochemical deficiency explains many of the motor disturbances encountered in patients with PD. However, the underlying cause of urinary dysfunction present in over half of patients with PD is poorly understood. Without clearly understanding the underlying pathophysiological and neurochemical mechanisms of LUTS associated with PD, treatment strategies are mainly empirical in nature. This review presents the most recent studies and evidence on the pathophysiological mechanisms of PD-related voiding dysfunction and its available therapies.
帕金森病（PD）患者随着疾病严重程度的进展，常出现下尿路症状（LUTS）。众所周知，黑质纹状体多巴胺能通路的神经退行性变发生在 PD 中。这种神经化学缺陷解释了 PD 患者遇到的许多运动障碍。然而，超过一半的 PD 患者存在的尿功能障碍的根本原因还不清楚。如果不能清楚地了解与 PD 相关的 LUTS 的潜在病理生理和神经化学机制，那么治疗策略主要是经验性的。本文综述了与 PD 相关的排尿功能障碍的病理生理机制及其现有治疗方法的最新研究和证据。
